Helminth infections Infections and Infestations
Conditions
Interventions
The participants who were diagnosed with helminthiases at the baseline parasitological survey were randomly allocated to the following arms:
Arm 1: Single-dose albendazole (oral), 200 mg for childre
Sponsors
Swiss National Science Foundation (SNSF) (Switzerland)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Both males and females, age >=5 years 2. Submission of >=1 stool sample for the baseline parasitological survey 3. For females, not pregnant, as verbally assessed by medical personnel on the day of treatment 4. Absence of major systemic illnesses, as assessed by medical personnel on the day of treatment 5. Written informed consent by the head of the household on behalf of the whole family
Exclusion criteria
Exclusion criteria: 1. Presence of any abnormal medical condition, as judged by the medical personnel 2. No stool sample submitted for baseline parasitological survey 3. Enrolled in any other clinical investigation during the study 4. For females: pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Reduction of infection prevalence of intestinal helminths, assessed by examination of stool samples 2-4 weeks after drug administration 2. Frequency and severity of adverse events were recorded within 24 hours after drug administration | — |
Secondary
| Measure | Time frame |
|---|---|
| Kato-Katz-derived egg count reduction of common soil-transmitted helminths, assessed 2-4 weeks after drug administration. | — |
Countries
China
Outcome results
None listed